Pemetrexed in the treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 43-48

  Shepherd, Frances A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VITAMIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; REVIEW; VITAMIN SUPPLEMENTATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; THYMIDYLATE SYNTHASE;

EID: 0036980955     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37415     Document Type: Review

References (21)

1. Chen VJ, Bewley JR, Andis SL, et al: Cellular pharmacology of MTA: A correlation of MTA induced cellular toxicity and in vitro enzyme inhibition with its effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol 26:48-54, 1999 (suppl 6)
2. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d] pyrimidine-based anti-folate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
3. Von Hoff DD: Human tumour cloning assays: Applications in clinical oncology and new anti-neoplastic agent development. Cancer Metastasis Rev 7:357-371, 1988
4. Shultz RM, Andis SL, Bewley JR, et al: Anti-tumor activity of the multi-targeted antifolate LY231514. Proc Am Assoc Cancer Res 37:380, 1996 (abstr 2597)
5. Rusthoven JJ, Eisenhauer E, Butts C, et al: Multitargeted anti-folate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: A phase II study. J Clin Oncol 17:1194-1199, 1999
6. Clarke SJ, Abratt R, Goedhals L, et al: Phase II trial pemetrexed disodium (Alimta, LY231514) in chemotherapynaïve patients with advanced non-small-cell lung cancer. Ann Oncol 13:737-741, 2002
7. Postmus P, Mattson K, von Pawel J, et al: Phase II trial of MTA (LY231514) in patients with non-small cell lung cancer who relapsed after previous platin or non-platinum chemotherapy. Lung Cancer 26:S249, 1999 (abstr 985)
8. Thödtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17:3009-3016, 1999
9. Manegold C, Gatzemeier U, Pawel R, et al: Front-line treatment of advanced non-small cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000
10. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung cancer. Cancer 92:595-600, 2001
11. Misset J-L, Gamelin E, Campone M, et al: Pemetrexed/oxaliplatin (LOHP) combination: Results of a phase I study in metastatic solid tumors. Proc Am Soc Clin Oncol 21:107a, 2002 (abstr 427)
12. Adjei AA: Combination studies with multitargeted antifolate LY231514, MTA, and gemcitabine in advanced solid tumors. Cancer Invest 18:102-103, 2000 (suppl 1) (abstr 79)
13. Adjei AA, Erlichman C, Sloan J, et al: A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent LY231514 (MTA) in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000
14. Le Chevalier T: Alimta in combination with Gemzar and other compounds. Lung Cancer 29:71-72, 2000
15. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
16. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. J Clin Oncol 18:2354-2362, 2000
17. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
18. Shepherd FA: Chemotherapy for non-small cell lung cancer: Have we reached a new plateau? Semin Oncol 26:3-11, 1999 (suppl 4)
19. Johnson DH, Zhu J, Schiller J, et al: E1594-A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC)-Outcome of PS2 patients: An Eastern Cooperative Group Trial. Proc Am Soc Clin Oncol 18:461a, 1999 (abstr 1779)
20. Shepherd FA: Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview. Anticancer Drugs 6:19-25, 1995
21. Shepherd FA, Abratt RP, Anderson H, et al: Gemcitabine in the treatment of elderly patients with advanced nonsmall cell lung cancer. Semin Oncol 24:50-55, 1997 (suppl 7)